Altimmune Inc (ALT)
7.20
+0.12
(+1.69%)
USD |
NASDAQ |
Apr 25, 16:00
7.21
+0.01
(+0.14%)
Pre-Market: 08:54
Altimmune Cash from Financing (Quarterly): 72.75M for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 72.75M |
| September 30, 2023 | 0.588M |
| June 30, 2023 | 13.06M |
| March 31, 2023 | -0.302M |
| December 31, 2022 | -0.043M |
| September 30, 2022 | 32.06M |
| June 30, 2022 | 21.58M |
| March 31, 2022 | 3.181M |
| December 31, 2021 | 12.54M |
| September 30, 2021 | 0.125M |
| June 30, 2021 | 18.02M |
| March 31, 2021 | 34.42M |
| December 31, 2020 | 22.70M |
| September 30, 2020 | 136.15M |
| June 30, 2020 | 54.54M |
| March 31, 2020 | 0.0967M |
| December 31, 2019 | 0.0449M |
| September 30, 2019 | -0.0558M |
| June 30, 2019 | -0.1561M |
| March 31, 2019 | 12.70M |
| December 31, 2018 | 31.52M |
| September 30, 2018 | 4.413M |
| June 30, 2018 | -3.460M |
| March 31, 2018 | 0.0185M |
| December 31, 2017 | 0.00 |
| Date | Value |
|---|---|
| September 30, 2017 | 12.99M |
| June 30, 2017 | -0.2008M |
| March 31, 2017 | 3.054M |
| December 31, 2016 | -0.6919M |
| September 30, 2016 | 2.060M |
| June 30, 2016 | 3.592M |
| March 31, 2016 | 0.0224M |
| December 31, 2015 | 0.0295M |
| September 30, 2015 | 0.317M |
| June 30, 2015 | 0.0422M |
| March 31, 2015 | -0.1657M |
| December 31, 2014 | 2.551M |
| September 30, 2014 | 10.50M |
| June 30, 2014 | 2.306M |
| March 31, 2014 | 1.377M |
| December 31, 2013 | 0.7917M |
| September 30, 2013 | 0.8403M |
| June 30, 2013 | 3.458M |
| March 31, 2013 | -0.0604M |
| December 31, 2012 | 0.1221M |
| September 30, 2012 | 1.208M |
| June 30, 2012 | -0.8151M |
| March 31, 2012 | 3.205M |
| December 31, 2011 | 0.0311M |
| September 30, 2011 | -0.0479M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.302M
Minimum
Mar 2023
136.15M
Maximum
Sep 2020
22.17M
Average
12.54M
Median
Dec 2021
Cash from Financing (Quarterly) Benchmarks
| Eli Lilly and Co | 3.545B |
| Amgen Inc | 2.754B |
| Viking Therapeutics Inc | 606.04M |
| Precision BioSciences Inc | 2.828M |
| Terns Pharmaceuticals Inc | 13.86M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -16.53M |
| Cash from Investing (Quarterly) | -7.959M |
| Free Cash Flow | -75.86M |
| Free Cash Flow Per Share (Quarterly) | -0.2826 |
| Free Cash Flow to Equity (Quarterly) | -16.53M |
| Free Cash Flow to Firm (Quarterly) | -16.53M |
| Free Cash Flow Yield | -19.79% |